Detail Data
Volume (24h): 2,508,943 shares
P/E Ratio: /
Forward P/E: -18.65
EPS: -1.21 USD
Forward EPS: -1.51 USD
Number of Shares: 112,310,000 shares
Market Capitalization: 3,162,649,600.00 USD

Dividend

Dividend Value
Dividend Amount According to our data, the company Viking Therapeutics does not currently pay dividends.
Annual Yield %: -
Ex-dividend Date: -
5-Year Avg Yield %: -
Payout Ratio: -
Last Dividend Value: -
Last Dividend Date: -

Analyst Forecast

Most analysts have issued a none recommendation for Viking Therapeutics stock. The current number of analysts covering this company is 19. The highest target price is 125 USD, while the lowest target price is 30 USD. The median target valuation set by analysts is 100 USD. These forecasts and recommendations provide insight into how analysts view the future stock performance of Viking Therapeutics.
Analysts Recommendation
Issued Recommendation: According to our data, the recommendation for Viking Therapeutics stock is: none
Number of Analysts: 19
Highest Target Price: 125 USD
Lowest Target Price: 30 USD
Median Target Price: 100 USD

Fundamental Indicators

Indicator Data
Total Revenue: /
Net Income: -128,236,000.00 USD
Price-to-Book (P/B): 3.73
PEG Ratio: /
Exchange: NasdaqCM
Industry: Biotechnology
Sector: Healthcare
Number of Employees: 36
Country: United States

Where to Buy Viking Therapeutics Stock?

You can purchase Viking Therapeutics stock on the NasdaqCM under the ticker symbol: VKTX. Several stock brokers or banks offer trading services for these stocks. Popular stock brokers like XTB and eToro allow you to buy real stocks and ETFs with zero or minimal commissions. Banks usually charge higher fees. Remember, investing in stocks involves risks, so it's important to carefully consider your financial situation and investment goals.

1

Real stocks and ETFs. Low minimum deposit, only 50 EUR. Option to copy trades. Advanced stock analysis and free education.

Trustpilot rating 4.4/5 Google play rating 4.2/5
Invest in Stocks with eToro
★★★★★ 5.0
2

Real stocks and ETFs + free demo account. Low fees + fast customer support. More than 5,200 instruments available for trading. Free training and education. Regular live streams on YouTube.

Trustpilot rating 3.6/5 Google play rating 4.5/5
Try Free Demo Account
★★★★☆ 4.8
Risk warning: Trading CFDs involves a high risk of financial loss. Between 51%-eToro -89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

More Information on Viking Therapeutics Stock

Indicator Value
Company Revenue: -
EBITDA: -
Earnings Per Share: -1.21 USD
Book Value Per Share: 7.54 USD
Total Cash: 851,857,984.00 USD
Total Cash per Share: 7.59 USD
Total Debt: 1,000,000.00 USD
Debt to Equity Ratio: 0.00
Quick Ratio 43.52
Current Ratio 44.25
Free Cash Flow -98,378,376.00 USD
Operating Cash Flow -133,987,000.00 USD
Gross Margins -
EBITDA Margins -
Operating Margins -
Profit Margins -
Return on Assets -11.7 %
Return on Equity -14.4 %
Earnings Growth (1 year) -
Revenue Growth (1 year) -
Quarterly Earnings Year-over-Year Growth -
Market Capitalization 3,162,649,600.00 USD
Enterprise Value 2,311,778,816.00 USD
EV/Revenue -
EV/EBITDA -
Float Shares 109,875,797 shares
Shares Outstanding 112,310,000 shares
Held Percent Insiders 0.02 %
Held Percent Institutions 70.15 %
Shares Short 25,543,738
Shares Short Prior Month 25,463,291
Date Short Interest 2025-05-15
Short Percentage of Total Shares 22.74 %
Short Ratio 6.49
Beta 0.75
Short Percentage of Float 27.29 %
Implied Shares Outstanding 112,310,000

Frequently Asked Questions (FAQ)

According to our data, the company Viking Therapeutics does not pay dividends yet, even in 2025.

Viking Therapeutics shares are traded on the NasdaqCM stock exchange under the ticker: VKTX. You can buy or trade them through a variety of stock brokers who provide real stock trading services.

According to our data, the recommendation for Viking Therapeutics shares is from a total of 19 analysts. The average target price prediction is 100 USD per share.

The total number of Viking Therapeutics shares on the exchange is 112,310,000.00 shares, which at the current market capitalization gives the company a total valuation of 3,162,649,600.00 USD.